Showing results (1-10 of 523) with videos related to
Sort By:
Pageof 53
Nederlands Tijdschrift Voor Geneeskunde|August 26, 2004
[New diagnostic criteria for multiple sclerosis in clinical practice]B W Van Oosten, F Barkhof, C H PolmanDrugs|February 1, 1995
Multiple sclerosis therapy. A practical guideB W van Oosten, L Truyen, F Barkhof, et al.Drugs|November 7, 1998
Choosing drug therapy for multiple sclerosis. An updateB W van Oosten, L Truyen, F Barkhof, et al.Archives of Neurology|June 17, 1998
Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosisB W van Oosten, F Barkhof, P E Scholten, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 1, 1996
A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosisB W van Oosten, M Lai, F Barkhof, et al.Neurology|December 1, 1996
Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosisL Truyen, J H van Waesberghe, M A van Walderveen, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|June 30, 2004
Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonistB W van Oosten, J Killestein, E M H Mathus-Vliegen, et al.Neurology|December 1, 1996
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2B W van Oosten, F Barkhof, L Truyen, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 3, 2002
Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisoloneE L J Hoogervorst, C H Polman, F BarkhofAnnals of Neurology|June 9, 1999
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosisA H van Boxel-Dezaire, S C Hoff, B W van Oosten, et al.Pageof 53